1. In Korean patients with achalasia, the short-term symptom relief after intrasphincteric botulinum toxin injection and balloon dilation treatment are similar. 2. Ballon dilatation had a better long-term outcome than that of intrasphincteric Botox injection in the treatment of achalasia. 3. Independent factors predicting long-term remission included treatment type and the difference in the lower esophageal sphincter pressure. The symptom-free period was significantly longer if the difference in LESP was > 19 mmHg, suggesting the usefulness of manometric follow-up after treatment.
1. Computed tomography (CT) score is helpful in assessment and management of amiodarone-induced pulmonary toxicity (APT) for symptomatic long term amiodarone user. 2. Especially, high APT CT score may be related with pulmonary insufficiency and rapid progress of respiratory failure. 3. There was little evidence of new development or recurrence of APT after discontinuing amiodarone.
1. In heart failure patients with ischemic origin, statin treatment is required in order to prevent second ischemic attack. 2. However, ‘too much’ lowering of cholesterol might not be beneficial in heart failure patients especially in functional capacity recovery.
1. High-flux (HF) dialysis was associated with a decreased mortality rate in prevalent hemodialysis (HD) patients, but not in incident HD patients. 2. The use of HF dialysis membranes should be recommended for prevalent patients.
1. Diffuse large B-cell lymphoma (DLBCL) can be subdivided into several subtypes according to the immunochemical features. 2. Nuclear factor κB (NF-κB) and CXCR4 were coexpressed in 80% of the patients. 3. The expression of NF-κB and CXCR4 may not be an independent prognostic marker for DLBCL patients treated with rituximab-CHOP.
1. Serial peripheral blood mononuclear cell enzymelinked immunosorbent spot assays during the course of treatment were found to be ineffective for predicting clinical response in patients with tuberculous meningitis (TBM). 2. Increases in tuberculosis (TB)-specific interferon- gamma producing T-cell response on cerebrospinal fluid-mononuclear cells during the early phase of anti-TB therapy may be predictive of clinical failure in patients with TBM.
1. Twelve weeks of etanercept treatment dramatically reduces systemic inflammation. 2. Levels of circulating bone metabolism markers—including c-telopeptide-1 and sclerostin—are elevated after etanercept treatment. 3. Short-term etanercept therapy appears to restore homeostasis in bone metabolism following chronic use of methotrexate and glucocorticoids.
1. Patients with malignancies related to idiopathic inflammatory myopathy (IIM) had a higher incidence of complex repetitive discharge (CRD) on electromyography (p = 0.008) as well as dysphagia (p < 0.001) and the absence of interstitial lung disease (p = 0.034) versus those without malignancies. 2. Multivariate logistic regression analysis revealed that the CRD conferred an odds ratio of 25.99 (95% confidence interval, 1.27 to 531.86; p = 0.034) for malignancy. 3. A higher number of risk factors may be a warning sign for hidden malignancies in IIM, suggesting the need for a thorough evaluation for malignancies.